95%(42)40 out of 42 people found this document helpful
This preview shows page 2 - 4 out of 4 pages.
genotypes are 2a, 2b (Europe, Japan), 2c (Northern Italy), 3a, 3b (India, Nepal, Pakistan), 4(Africa and Middle East), 5 (South Africa), 6 (Hong Kong and Southeast Asia) (Nouroz,Shaheen, Mujtaba, & Noreen, 2015).Therefore, there are multiple types of treatment based ongenotype, therefore the treatment plan for this patient will be for Genotype 1a naïve, non-HIVinfected and without cirrhosis. This is due to Genotype 1a being the most prevalent in the UnitedStates.The options for treating Genotype 1a are: 1. Epclusa (Sofosbuvir/Velpatasvir), 2.Mavyret (Glecaprevir/Pibrentasvir), Harvoni (Ledipasvir/Sofosbuvir), 4. Zepatier(Elbasvir/Grazoprevir) (Journal of Hepatology, 2018).The patient will need the RNA viral loadmonitored for 12-16 weeks before starting treatment in the acute phase.So, therefore after that
time has passed since the scenario said the patient possibly had Hepatitis C.The patient will alsohave to have a negative drug and alcohol screen before treatment is initiated as treatment iscostly and therapy is not initiated until the patient is compliant.The patient will be started onHarvoni treatment which is 90mg Ledipasvir/400mg Sofosbuvir, which is one tablet by mouthdaily for eight weeks.This treatment plan does not interfere with any of the current medicationsthe patient is prescribed.ReferencesAmerican Association for the Study of Liver Diseases. (2018).HCV Guidelines. Retrieved fromArcangelo, V. P., Peterson, A. M., Wilbur, V., & Reinhold, J. A. (2017).Pharmacokinetics foradvanced practice: A practical approach(4th ed.). Ambler, PA: Lippincott Williams &Wilkins.